EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could some breast cancer patients skip extra treatment? new trial investigates
Disease control Recruiting nowThis phase II trial is testing whether patients with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to reduce side effects w…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could breast cancer patients skip extra immunotherapy? major trial aims to find out
Disease control Recruiting nowThis phase 3 trial is for people with early-stage triple-negative breast cancer who had a complete response to chemotherapy plus the immunotherapy drug pembrolizumab before surgery. It compares continuing pembrolizumab for 27 weeks after surgery versus simply watching and waiting…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise in early breast cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Custom-Made vaccine takes on aggressive breast cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attac…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Could a shorter, less toxic treatment be just as effective for early breast cancer?
Disease control Recruiting nowThis study is for people with early-stage triple-negative breast cancer. It compares a shorter chemo-immunotherapy regimen without anthracyclines (a type of strong chemo) to the usual longer treatment. The goal is to see if the shorter approach works just as well while reducing s…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC